Overview of Patient Management and Future Directions in Unknown Primary Carcinoma

Seminars in Oncology

Volumn 36, Issue 1, 2009, Pages 75-80

  Varadhachary, Gauri R ^a   Greco, F Anthony ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CLINICAL FEATURE; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; METASTASIS; MICROARRAY ANALYSIS; MICROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE RAS; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TONSILLECTOMY;

HUMANS; NEOPLASMS, UNKNOWN PRIMARY;

EID: 58549084635     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.10.008     Document Type: Article

References (22)

1. Greco F.A., and Hainsworth J.D. Cancer of unknown primary site. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice oncology. 8th ed. (2008), Lippincott, Philadelphia 2363-2387
2. Pantou D., Tsarouha H., Papadopoulou A., et al. Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management. Neoplasia 5 (2003) 23-31
3. Bar-Eli M., Abbruzzese J.L., Lee-Jackson D., et al. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 13 (1993) 1619-1623
4. Hainsworth J.D., Lennington W.J., and Greco F.A. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18 (2000) 632-635
5. Pavlidis N., Briassoulis E., Bai M., et al. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 15 (1995) 2563-2567
6. Hillen H.F., Hak L.E., Joosten-Achjanie S.R., et al. Microvessel density in unknown primary tumors. Int J Cancer 74 (1997) 81-85
7. Karavasilis V., Malamou-Mitsi V., Briasoulis E., et al. Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 5 (2005) 25
8. Tothill R.W., Kowalczyk A., Rischin D., et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 65 (2005) 4031-4040
9. Varadhachary G., Talantov D., Raber M., et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26 (2008) 4442-4448
10. Olson Jr. J.A., Morris E.A., Van Zee K.J., et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 7 (2000) 411-415
11. Orel S.G., Weinstein S.P., Schnall M.D., et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 212 (1999) 543-549
12. Koch W.M., Bhatti N., Williams M.F., et al. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg 124 (2001) 331-333
13. Lassen U., Daugaard G., Eigtved A., et al. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 35 (1999) 1076-1082
14. Regelink G., Brouwer J., de Bree R., et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging 29 (2002) 1024-1030
15. Rusthoven K.E., Koshy M., and Paulino A.C. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101 (2004) 2641-2649
16. Kolesnikov-Gauthier H., Levy E., Merlet P., et al. FDG PET in patients with cancer of an unknown primary. Nucl Med Commun 26 (2005) 1059-1066
17. Pelosi E., Pennone M., Deandreis D., et al. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 50 (2006) 15-22
18. Nanni C., Rubello D., Castellucci P., et al. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 32 (2005) 589-592
19. Varadhachary G.R., Abbruzzese J.L., and Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 100 (2004) 1776-1785
20. Roh M.S., and Hong S.H. Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes. J Korean Med Sci 17 (2002) 512-517
21. Tan D., Li Q., Deeb G., et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 34 (2003) 597-604
22. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 38 (2002) 758-763